Bright Rock Capital Management LLC Takes $6.79 Million Position in Zoetis Inc. $ZTS

Bright Rock Capital Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, HoldingsChannel reports. The fund acquired 54,000 shares of the company’s stock, valued at approximately $6,794,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the fourth quarter worth about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis during the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis in the fourth quarter valued at $32,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Zoetis in the 4th quarter valued at about $38,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZTS. Barclays assumed coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Morgan Stanley set a $160.00 price target on Zoetis in a research note on Thursday, December 18th. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. The Goldman Sachs Group raised Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Trading Up 2.7%

ZTS opened at $116.41 on Tuesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a fifty day moving average of $123.23 and a 200-day moving average of $128.79. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23. The stock has a market cap of $49.14 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 1.73 and a beta of 0.95.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.